Description

Brain Injury Medicine providers routinely prescribe medications to address various acute and chronic sequelae. Providers attempting to optimize treatment regimens in this vulnerable population often use medications that are off-label or which have not been studied extensively in brain injury. Results of newer or small studies may not yet be widely known in the field.         

This session will try to fill in that knowledge gap. Faculty members will discuss common problems, with potential medication treatments, through a discussion of cases. The faculty will also present didactic-style information about pertinent updates in this topic area. The panel will discuss points in the cases where they might choose different medications. This interactive session will allow participants to ask questions and provide comments.    

The overall goal of these conversations will be for learners to review best practices for medication management for sequalae of brain injury. Specific clinical situations to be addressed include: paroxysmal sympathetic hyperactivity, agitation, disordered consciousness, and behavioral dysregulation. Discussion about rationales for medication choices will include information about potential neurotransmitter derangements and implications for treatment. Speakers will present a review of classic and recent literature as we try to move toward use of best practices in this important part of our field. 

Learning Objectives

• Learning Objective 1: Describe common neurotransmitter derangements that occur during recovery from brain injury.
• Learning Objective 2: Discuss best practice for medication options for common problems seen in brain injury rehabilitation.
• Learning Objective 3: Demonstrate ability to list appropriate medication choices for common brain injury sequelae.

Accreditation Statement
The American Academy of Physical Medicine and Rehabilitation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.  

Financial Disclosures
AAPM&R requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest, which is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. Disclosures are made in written form prior to the start of the educational activity and any potential conflicts of interest that exist are resolved prior to the start of the activity through AAPM&R’s Conflict of Interest Disclosure and Resolution Policy Process. Individuals in a position to control content and their disclosed financial relationships are listed below.

Faculty
Session Director: Diane Mortimer, MD, DO, FAAPMR: Disclosed no relevant financial relationships.
Sheital Bavishi, DO, FAAPMR: Disclosed no relevant financial relationships.    
Matthew Puderbaugh, DO, FAAPMR: Disclosed no relevant financial relationships.        
Sara Liegel, MD, FAAPMR: Disclosed no relevant financial relationships.        
Ashley Mohan, DO, FAAPMR: Disclosed no relevant financial relationships.    

AAPM&R Medical Education Committee
John C. Cianca, MD: Ownership or partnership with Musculoskeletal Ultrasound Consultants, LLC.
Karen P. Barr, MD: Disclosed no relevant financial relationships.
Rachel A. Brakke Holman, MD: Disclosed no relevant financial relationships.
Joseph E. Burris, MD: Serves on the Speakers Bureau for, and received clinical research grants from Allergan.
David S. Cheng, MD: Disclosed no relevant financial relationships.
Theresa A. Gillis, MD: Disclosed no relevant financial relationships.
Kevin N. Hakimi, MD: Disclosed no relevant financial relationships.
Matthew T. Haas, MD: Disclosed no relevant financial relationships.
R.Samuel Mayer, MD: Royalties from Demos Medical Publishing.
Ameet S. Nagpal, MD MS MEd: Disclosed no relevant financial relationships.
Sunil Sabharwal, MD: Royalities from Demos Publishing; board member, American Board of Physical Medicine and Rehabilitation.
Sarah M. Smith, MD: Disclosed no relevant financial relationships.
Stephanie Tow, MD: Disclosed no relevant financial relationships.
Kevin R. VIncent, MD, PhD: Disclosed no relevant financial relationships.

AAPM&R CME Committee
Karen P. Barr, MD: Disclosed no relevant financial relationships.
Cherry C. Junn, MD: Disclosed no relevant financial relationships.
Sheryl R. Levin, MD: Disclosed no relevant financial relationships.
Kentaro Onishi, DO: Disclosed no relevant financial relationships.
Evan R. Peck, MD: Disclosed no relevant financial relationships.
Cynthia G. Pineda, MD: Disclosed no relevant financial relationships.
Patricia T. Tan, MD: Disclosed no relevant financial relationships.
Brionn K. Tonkin, MD: Disclosed no relevant financial relationships.
Kristin A. Wong, MD: Disclosed no relevant financial relationships.

No other planners, faculty or other individuals in control of content disclosed any relevant financial relationships.

FDA Disclosures
All faculty members for this activity have disclosed they do not intend to discuss or demonstrate any pharmaceutical or medical device for which FDA clearance has not been approved.